What is a good starting dose for an Angiotensin-Converting Enzyme (ACE) inhibitor for heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For heart failure, a good starting dose of an ACE inhibitor is typically low, such as lisinopril at 2.5-5 mg once daily, enalapril at 2.5 mg twice daily, or ramipril at 1.25-2.5 mg once daily, and then gradually increased as tolerated. These lower initial doses are particularly important for patients who may be at risk for hypotension, including those on diuretics, the elderly, or those with renal impairment.

Key Considerations

  • The dose should be doubled approximately every 2 weeks as tolerated until reaching the target dose (lisinopril 20-40 mg daily, enalapril 10-20 mg twice daily, or ramipril 10 mg daily) or the maximum tolerated dose 1.
  • Blood pressure, renal function, and potassium levels should be monitored within 1-2 weeks after initiation and after each dose increase 1.
  • ACE inhibitors work by blocking the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and sodium retention, which decreases cardiac workload and improves symptoms and survival in heart failure patients.

Monitoring and Adjustments

  • Renal function and serum potassium should be assessed within 1 to 2 weeks of initiation of therapy and periodically thereafter, especially in patients with preexisting hypotension, hyponatremia, diabetes mellitus, azotemia, or in those taking potassium supplements 1.
  • A specialist HF nurse may assist with education of the patient, follow-up, biochemical monitoring, and dose up-titration 1.

Evidence-Based Recommendations

  • The available data suggest that there are no differences among ACE inhibitors in their effects on symptoms or survival 1.
  • Treatment with an ACE inhibitor should be initiated at low doses, followed by gradual dose increments if lower doses have been well tolerated 1.

From the FDA Drug Label

In the placebo-controlled studies that demonstrated improved survival, patients were titrated as tolerated up to 40 mg, administered in two divided doses. The recommended initial dose is 2.5 mg. The recommended dosing range is 2. 5 to 20 mg given twice a day. Doses should be titrated upward, as tolerated, over a period of a few days or weeks.

  • Initial dose: 2.5 mg
  • Dosing range: 2.5 to 20 mg given twice a day
  • Titration: upward, as tolerated, over a few days or weeks 2

From the Research

Starting Dose for ACE Inhibitors in Heart Failure

  • The optimal starting dose for ACE inhibitors in heart failure is not explicitly stated in the provided studies, but it is recommended to start with a low dose and titrate up to the target dose used in clinical trials, if tolerated 3.
  • A study comparing enalapril and perindopril found that a low dose of 2.5 mg enalapril or 2.0 mg perindopril was used as the starting dose, with perindopril causing less first-dose hypotension 4.
  • Another study used perindopril as the starting ACE inhibitor, with a target dose of at least 4 mg/day, and found that specialist heart failure nurse supervised rapid titration to target dose was safe and feasible in a community heart failure population 5.

Target Dose for ACE Inhibitors in Heart Failure

  • The target dose for ACE inhibitors in heart failure is the dose used in clinical trials, which has been shown to reduce morbidity and mortality 3, 6.
  • Examples of target doses for specific ACE inhibitors include:
    • Captopril: 50-100 mg/day 6
    • Enalapril: 10-20 mg/day 6
    • Lisinopril: 20-40 mg/day 6
    • Ramipril: 5-10 mg/day 6
  • A systematic review and meta-analysis found that high-dose ACE inhibitors did not significantly reduce all-cause or cardiovascular mortality compared to low-dose ACE inhibitors, but did increase functional capacity and the risk of hypotension 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.